Business Roundtable
Redefining the EXIT Strategy
Wednesday, February 13, 2008
9:30 AM
Conrad Suite
Liquidity and access to Wall Street money is the goal of most biotechnology companies to fulfill the capital needs of an emerging pipeline of products. The traditional IPO is still valid, but the bar is rising each year. This panel will explore what it takes to do a successful IPO today and the pros and cons of the more creative approaches to achieving public status, including M&A, foreign exchanges, reverse mergers, etc.
Moderators
- Peter Wysong; Managing Director, Natixis Bleichroeder Inc.
Panelists
- Bob Power; VP, Global Corporate Client Group, NYSE Euronext
- Tracy Lefteroff; Global Managing Partner, Life Sciences Industry Services, Pricewaterhouse Coopers
- Kevin Collins; Shareholder, Heller Ehrman LLP
- Hervé Brailly, PhD; President and CEO, Innate-Pharma SA